Tobacco Use Disorder | A Brain Imaging Study Into Nicotine Induced Dopamine Release in Cigarette Smokers.
Tobacco Use Disorder research study
What is the primary objective of this study?
Dopamine (DA) plays a critical role in nicotine (and other) addiction and this drug is known to release DA in brain areas mediating reward and motivational processes. Although imaging studies show that release of DA follows smoking, little is known regarding how common genetic polymorphisms for three genes associated in some studies with smoking (dopamine D2 receptor, dopamine and serotonin transporter) interact with smoking status and modulate individual differences in nicotine-induced DA release and dopamine receptor occupancy, in vivo. The current proposal combines brain imaging and genomics ('imaging genomics') towards partially unraveling the complex relationship between smoking phenotype and common polymorphisms. Understanding whether genetic factors contribute to inter-individual variability in smoking is crucial for interpreting imaging results in the context of disease pathology. We hypothesize that a model of vulnerability to addiction based on interactions between genotype, receptor and transporter availability and in vivo nicotine-induced DA release will elucidate some of the fundamental neurochemical and neurogenetic circuits underlying addiction.
Who is eligible to participate?
Inclusion Criteria: - smokers who smoked 15 cigarettes/day and who met the DSM-IV criteria for nicotine dependence Exclusion Criteria: - Subjects who are diagnosed as suffering from psychotic illness according to DSM-IV (Axis 1)22, or with a history of CNS disease, a history of infection that might affect CNS (HIV, syphilis, cytomegalovirus, herpes), or a history of head injury with loss of consciousness will be excluded.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Tobacco Use Disorder
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:BupropionWe measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
Drug:BupropionBrain imaging after treatment with Bupropion
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: July 2007
Completed Date: July 2012
Primary Outcome: Dopamine D2 receptor occupancy before and after smoking a cigarette with nicotine
Secondary Outcome: Subjective measures of craving, anxiety and depression.
Study sponsors, principal investigator, and references
Principal Investigator: Aviv M Weinstein, Ph.D
Lead Sponsor: Hadassah Medical Organization